Abemaciclib as adjuvant treatment for high-risk early breast cancer

CONCLUSIONS: The results of the pivotal trial are sufficient to consider abemaciclib as adjuvant treatment for high-risk early breast cancer in highly selected patients. However, in order to the efficacy results present less uncertainty, we must wait for a evaluation later, in which we can have a mature determination at 3 years (with more patients at risk).PMID:37735004 | DOI:10.1016/j.farma.2023.08.006

Source: Farmacia Hospitalaria - September 21, 2023 Category: Drugs & Pharmacology Authors: Ganfornina Andrades Ana F énix Caballero Silvia Salguero Olid Alba Alegre Del-Rey Emilio Jes ús Source Type: research